BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15984997)

  • 1. Tuberculous peritonitis.
    Finlay DG; Szauter K; Raju GS; Snyder N
    Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
    Matsumoto T; Tanaka T; Kawase I
    N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
    [No Abstract]   [Full Text] [Related]  

  • 4. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy.
    Iliopoulos A; Psathakis K; Aslanidis S; Skagias L; Sfikakis PP
    Int J Tuberc Lung Dis; 2006 May; 10(5):588-90. PubMed ID: 16704045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 6. Tuberculous peritonitis during infliximab therapy.
    Verhave JC; van Altena R; Wijnands MJ; Roerdink HT
    Neth J Med; 2008 Feb; 66(2):77-80. PubMed ID: 18292611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculous peritonitis after treatment with adalimumab.
    Antolín J; Azahara M; Hernández C; Blanco M; Mao L; Cigüenza R
    Scand J Infect Dis; 2008; 40(8):677-8. PubMed ID: 18979608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
    Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
    Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
    [No Abstract]   [Full Text] [Related]  

  • 10. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
    Montagna GL; Malesci D; Buono R; Valentini G
    Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
    [No Abstract]   [Full Text] [Related]  

  • 11. Survival and safety of treatment with infliximab in the elderly population.
    Chevillotte-Maillard H; Ornetti P; Mistrih R; Sidot C; Dupuis J; Dellas JA; Tavernier C; Maillefert JF
    Rheumatology (Oxford); 2005 May; 44(5):695-6. PubMed ID: 15705631
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.
    Yoo WH
    Rheumatol Int; 2012 Mar; 32(3):787-90. PubMed ID: 20049444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab.
    Conti F; Priori R; Chimenti MS; Coari G; Annovazzi A; Valesini G; Signore A
    Arthritis Rheum; 2005 Apr; 52(4):1224-6. PubMed ID: 15818709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 16. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 17. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 18. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
    Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
    [No Abstract]   [Full Text] [Related]  

  • 20. [Miliary tuberculosis and tuberculous peritonitis during infliximab treatment for rheumatoid arthritis].
    Oguri T; Ito S; Morishita M; Sakamoto K; Kondo M; Hasegawa Y
    Nihon Kokyuki Gakkai Zasshi; 2010 Mar; 48(3):192-7. PubMed ID: 20387522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.